AIS Biotech is developing glycomimetic-based anti-infectives that act as decoys to prevent pathogen adhesion, bypassing resistance mechanisms. Its lead product, GlycoFlu, is a universal nasal spray active against all influenza strains, without annual adaptation, offering a complementary solution to vaccines. The company leverages a scalable, eco-friendly bioproduction platform enabling expansion into a broad pipeline of viral and bacterial targets.